Nimbus Discovery Presents Compelling Preclinical Proof of Concept Data on Novel ACC Allosteric Inhibitor ND-630 Nimbus Discovery LLC, a biotechnology company discovering novel medicines against exciting but previously inaccessible drug targets, presented preclinical data today that show that the company’s Acetyl CoA Carboxylase allosteric inhibitor, ND-630, improves insulin sensitivity; produces a dose dependent reduction in whole body fat markers; and decreases triglycerides, fatty acids and cholesterol ...
June 22, 2013 - Business Wire via Yahoo! Finance